Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer.
10.4166/kjg.2015.66.3.150
- Author:
Ji Kon RYU
1
Author Information
1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. jkryu@snu.ac.kr
- Publication Type:English Abstract ; Review
- Keywords:
Pancreatic neoplasms;
Drug therapy
- MeSH:
Adenocarcinoma/*drug therapy/pathology;
Antimetabolites, Antineoplastic/therapeutic use;
Antineoplastic Agents/therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use;
Deoxycytidine/analogs & derivatives/therapeutic use;
Humans;
Immunotherapy;
Pancreatic Neoplasms/*drug therapy/pathology;
Protein Kinase Inhibitors/therapeutic use
- From:The Korean Journal of Gastroenterology
2015;66(3):150-153
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic agent since 1997, but survival benefit is not satisfactory. Recent clinical study proved that several new combination chemotherapy regimens are superior to gemcitabine single chemotherapy and extended overall survival. However, its prognosis still remains grim. Current research is taking a multidirectional approach in the hope of developing more effective treatments. This article reviews the major clinical trial data that is the basis for the current chemotherapy regimens used as first- and second-line treatments for advanced pancreatic adenocarcinoma. This article also reviews the current ongoing clinical trials, which include the use of molecular targeting agents and immune therapies.
